BFRI Biofrontera Inc.

Biotech Analyst Ratings

Latest News

1. 16 May 2022 Biofrontera Inc. Announces Pricing of $9.4 Million Private Placement

   WOBURN, MA., May 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera, Inc. (NASDAQ:BFRI, BFRIW))), announced today that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 3,419,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 3,419,000 shares of common stock, in a private placement. The purchase price for one share of common stock (or common stock equivalent) and a warrant to purchase one share of common stock is $2.75. The warrants have an exercise price of $2.77 per share, will be exercisable six months after issue date, and will expire five and one-half years from the issuance date.
   

   Roth Capital Partners and The…

   View Full Article
2. 13 May 2022 Biofrontera Inc. Reports First Quarter 2022 Financial Results and Provides a Business Update

   Conference call begins at 11:00 a.m. Eastern time today
   

   WOBURN, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial results for the three months ended March 31, 2022, and provided a business update.

   Financial Highlights & Recent News

   • Total revenues for the first quarter of 2022 were $9.8 million, an increase of 106% from the first quarter of 2021
   • Cash and cash equivalents were $22.4 million as of March 31, 2022, compared with $24.5 million as of December 31, 2021
   • Created a dedicated key accounts team to address the changing landscape of the dermatology industry, and advanced plans…

   View Full Article
3. 06 May 2022 Biofrontera Inc. to Report First Quarter Financial Results on May 13, 2022

   WOBURN, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, will report financial results for the three months ended March 31, 2022 before the opening of the U.S. financial markets on Friday, May 13, 2022 and will hold a conference call that same day beginning at 11:00 a.m. Eastern time to discuss those results, provide a business update and answer questions.
   

   Conference Call and Webcast Information

   Event:	Biofrontera Inc. First Quarter 2022 Financial Results and Business Update Conference Call
   Date:	Friday, May 13, 2022
   Time:	11:00 a.m. Eastern time
   Conference call:	1-877-877-1275 (U.S.) 1-412-858-5202 (international)
   Webcast:	Live

   …

   View Full Article
4. 05 May 2022 Biofrontera Inc. to Showcase Actinic Keratosis Treatments at the Music City Symposium for Cosmetic Advances & Laser Education

   Live Demonstration of New RhodoLED^® XL to be Featured

   WOBURN, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today its sponsorship of the 17^th Edition of the Music City Symposium for Cosmetic Advances & Laser Education (SCALE), being held May 11-15, 2022 in Nashville, Tenn. As a Sponsor, Biofrontera will be hosting a booth showcasing its innovative, FDA-approved products and featuring its new RhodoLED^® XL illumination lamp used in photodynamic therapy (PDT) for treating actinic keratosis (AK). On Saturday, May 14, 2022, Dr. Michael Gold, M.D., a board-certified dermatologist, cosmetic surgeon and founder of Gold…

   View Full Article
5. 21 April 2022 Biofrontera Launches New Patient-Focused Websites for Ameluz® and Xepi®

   Ameluz^® for the treatment of actinic keratoses now at www.ameluz.com
   Xepi^® for the treatment of impetigo now at www.xepicream.com

   WOBURN, Mass. , April 21, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the launch of new and updated websites for its two products, Ameluz^® and Xepi^®. Now each brand has two websites in one featuring a patient-focused and a healthcare professional (HCP)-focused website with appropriate content for both audiences.

   To view the new websites, please visit www.ameluz.com for Ameluz^® or www.xepicream.com for Xepi^®.

   "A full team of Biofrontera employees provided multidisciplinary…

   View Full Article